Document:

Stock Option Agreement

 
Exhibit 10.1

 
Magma Design
Automation, Inc. 
 
ID:
77-0454924 
 
2 Results Way

 
Cupertino, CA 95014

 
 
Notice of Grant of Stock Options 
and Option Agreement

 
 

	 Roy E. Jewell
	 	 	 	 Option Number:
	 	 0001355

	 2 Results Way
	 	 	 	 Plan:
	 	 2001

	 Cupertino, CA 95014
	 	 	 	 ID:
	 	 

 
 
Effective 5/14/2003, you have been granted a(n) Non-Qualified Stock Option to buy 297,393 shares of Magma Design Automation, Inc. (the Company) stock at
$7.00000 per share. 
 
The total option price of the shares granted
is $2,081,751.00. 
 
Shares in each period will become fully vested
on the date shown. 
 

	 Shares
	 	 Vest Type
	 	 Full Vest
	 	 Expiration

	
	     297,393
	 	     On Vest Date
	 	     5/5/2005
	 	     5/14/2013

 
 
 
 
By
your signature and the Company’s signature below, you and the Company agree that these options are granted under and governed by the terms and conditions of the Company’s Stock Option Plan as amended and the Option Agreement, all of which
are attached and made a part of this document. 
 

	
	 /s/  Magma Design Automation, Inc.
	 	 Date 5/19/03

	
	 /s/  Roy E. Jewell
	 	 Date 5/19/03

 
STOCK OPTION
AGREEMENT 
 
TERMS AND CONDITIONS

 
MAGMA DESIGN AUTOMATION, INC.

 
2001 Stock Incentive Plan

 
THIS STOCK OPTION AGREEMENT TERMS AND
CONDITIONS (the “Stock Option Agreement Terms and Conditions”), together with the Notice of Stock Option Grant (the “Notice of Grant”) to which this Stock Option Agreement Terms and Conditions is attached, constitute the Stock
Option Agreement referred to in the Magma Design Automation, Inc. 2001 Stock Incentive Plan (the “Plan”) with respect to the option granted to you pursuant to the Notice of Grant (the “Option”). This Option is intended to be an
Incentive Stock Option or a Nonstatutory Stock Option, as provided in the Notice of Grant. 
 
1.    Exercise.  The Option evidenced by this Stock Option Agreement Terms and Conditions becomes exercisable in equal installments on a monthly basis over
twenty-two (22) months, beginning one month after your vesting commencement date, May 5, 2003, and ending March 5, 2005. Your rights to exercise the Option accrue only for the time period you render Service to the Company following your vesting
commencement date. 
 
2.    Term.  The Option expires on the date shown in the Notice of Grant, but in no event later than the tenth anniversary of the Date of Grant set forth in the Notice of Grant. The Option
may expire earlier in connection with the termination of your Service, as described below. 
 
3.    Regular Termination.  If your Service with the Company or a Subsidiary terminates for any reason excluding death, Total and Permanent Disability or
Cause, this Option will expire on the date three months after your termination date. 
 
4.    Death or Disability.  If your Service with the Company or a Subsidiary terminates as a result of your Total and Permanent Disability or death, this Option will expire on the
date six months after your termination date. If the Option is an Incentive Stock Option, the Stock Option will cease to be treated as an Incentive Stock Option if not exercised within three (3) months after termination of Service. 
 
5.    Cause.  If your Service with
the Company or a Subsidiary terminates for Cause, this Option will expire on the date seven days following your termination date. For purposes of this section, Cause shall mean (i) continued failure to perform substantially your duties, which
standard of duties shall be referenced to the standards set by the Company at the date of this Agreement (other than as a result of sickness, accident or similar cause beyond your reasonable control) after receipt of a written warning and your being
given thirty (30) days to cure the failure; (ii) willful misconduct or gross negligence, which is demonstrably injurious to the Company or any of its subsidiaries, including without limitation willful or grossly negligent failure to perform your
material duties as an officer or employee of the Company or any of its subsidiaries or a material breach of this Agreement, your employment agreement (if any) or your Proprietary Information and Inventions Agreement with the Company; (iii)
conviction of or plea of nolo contendere to a felony; or (iv) commission of an act of fraud against, or 

the misappropriation of property belonging to, the Company or any affiliated company, employee, customer or supplier of the Company.

 
6.    Leaves of
Absence.  For purposes of this Option, your Service does not terminate when you go on a military leave of absence, a sick leave of absence or another bona fide leave of absence, if the leave of absence was approved by the Company
in writing and if continued crediting of Service is required by the terms of the leave or by applicable law. Your Service will terminate when the approved leave of absence ends unless you immediately return to active work. Except as provided by
applicable law, or unless expressly provided in writing pursuant to a Company-approved leave of absence, the period of the approved leave of absence will not be credited as Service to the Company for the purposes of determining when your Option
vests. In accordance with the preceding sentence, the dates on which the Option would otherwise vest will be postponed by the number of days of the approved leave of absence. 
 
7.    Restrictions on Exercise.  The Company will not permit you to exercise this
Option if the issuance of Shares at that time would violate any law or regulation. 
 
8.    Notice of Exercise.  When you wish to exercise this Option you must notify the Company by completing the Notice of Stock Option Exercise in the form attached to this Stock
Option Agreement Terms and Conditions (or such other form approved by the Company) (the “Notice of Exercise”) and filing it with the Treasury Department of the Company. The exercise of your Option will be effective when the Notice of
Exercise and payment of the Exercise Price is received by the Company. In the case of a cashless exercise through a securities broker approved by the Company, the Notice of Exercise form must be filed in advance and approved by the Company prior to
placing the order with the broker. This Notice of Exercise form may be superseded by a Company-sponsored web-based trading program that includes security measures sufficient to ensure your identification, such that your entry of a web-based exercise
or cashless exercise constitutes your request and authorization to exercise the Option. If someone else wants to exercise this Option after your death, that person must prove to the Company’s satisfaction that he or she is entitled to do so.

 
9.    Form of
Payment.  Payment may be made (i) by personal check, a cashier’s check or a money order, (ii) in shares of Company Stock which have been owned by you or your representative for more than twelve (12) months and which are
surrendered to the Company in good form for transfer, or (iii) by delivering a Committee-approved form of irrevocable direction to a securities broker approved by the Company to sell all or part of the Shares subject to the Option and to deliver to
the Company from the sale proceeds an amount sufficient to pay the Exercise Price and any withholding taxes. In the case of a cashless exercise, the balance of the sale proceeds will be delivered to you. Notwithstanding the foregoing, a form of
payment will not be available if the Committee determines, in its sole and absolute discretion, that such form of payment could violate any law or regulation. 
 
10.    Withholding Taxes and Stock Withholding.  You will not be allowed to exercise this Option unless you
make arrangements acceptable to the Company to pay any withholding taxes that may be due as a result of the Option exercise. These arrangements may include withholding Shares of Company Stock that otherwise would be issued to you when you exercise
this Option. The value of these Shares, determined as of the effective date of Option exercise, will be applied to the withholding taxes. 

 
11.    Restrictions on Resale.  By entering into this Stock Option Agreement Terms and Conditions, you agree not to sell any Shares at a time when applicable laws or Company policies
prohibit a sale. This restriction will apply as long as you are providing Service to the Company or a Subsidiary. 
 
12.    Transfer of Option.  Prior to your death, only you can exercise this Option. You cannot transfer or
assign this Option. For instance, you may not sell this Option or use it as security for a loan. If you attempt to do any of these things, this Option will immediately become invalid. You may in any event dispose of this Option in your will.
Regardless of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your former spouse, nor is the Company obligated to recognize your former spouse’s interest in your Option in any other
way. 
 
13.    Retention
Rights.  Neither your Option nor this Stock Option Agreement Terms and Conditions give you the right to be retained by the Company or a Subsidiary in any capacity. The Company and its subsidiaries reserve the right to terminate
your Service at any time, with or without Cause. 
 
14.    Stockholder Rights.  You have no rights as a stockholder of the Company until you have exercised this Option by giving the required Notice of Exercise to the Company and paying the
Exercise Price. No adjustments are made for dividends or other rights if the applicable record date occurs before you exercise this Option, except as described in the Plan. 
 
15.    Adjustments.  In the event of a stock split, a stock dividend or a similar
change in Company Stock, the number of Shares subject to this Option and the Exercise Price per share may be adjusted pursuant to the Plan. 
 
16.    Applicable Law.  This Stock Option Agreement Terms and Conditions will be interpreted and enforced
under the laws of the State of California (without regard to choice-of-law provisions). 
 
17.    The Plan and Other Agreements.  The text of the Plan is incorporated in this Stock Option Agreement Terms and Conditions by reference. Capitalized terms used herein and not
defined shall have the meanings set forth in the Plan. This Stock Option Agreement Terms and Conditions, the Notice of Grant, the Notice of Exercise and the Plan constitute the entire understanding between you and the Company regarding this Option.
Any prior agreements, commitments or negotiations concerning the Option are superseded. This Stock Option Agreement Terms and Conditions, the Notice of Grant and the Notice of Exercise may be amended only by another written agreement, signed by both
you and the Company. 
 
BY SIGNING THE NOTICE OF
GRANT, YOU AGREE TO ALL OF THE 
TERMS AND CONDITIONS DESCRIBED IN THE NOTICE OF GRANT, THE 
STOCK OPTION AGREEMENT TERMS AND CONDITIONS, THE NOTICE OF EXERCISE 
AND THE PLAN, AND ACKNOWLEDGE RECEIPT OF A COPY OF THE PLAN.Amendment to Rights Agreement

Exhibit 4.7 
 
AMENDMENT TO RIGHTS AGREEMENT 
BETWEEN TULARIK INC. AND 
WELLS FARGO BANK
MINNESOTA, N.A. 
 
THIS
AMENDMENT TO RIGHTS AGREEMENT (the “Amendment”) is made this 21st day of May, 2003, by and between TULARIK INC., a Delaware
corporation (the “Company”), and WELLS FARGO BANK MINNESOTA, N.A. (the “Rights Agent”). 
 
WHEREAS, the Company and Amgen Inc., a Delaware corporation (“Amgen”), are
entering into that certain Collaboration and License Agreement dated as of May 21, 2003 (the “Collaboration”); 
 
WHEREAS, in connection with the Collaboration, the Company is entering into a Stock Purchase Agreement dated as of
May 21, 2003 (as the same may be amended from time to time, the “Stock Purchase Agreement”), between the Company and Amgen, pursuant to which Amgen will purchase newly issued shares of common stock from the Company; 
 
WHEREAS, it is in the best interest of
the Company to facilitate the transfer by ZKB Pharma Vision AG of all of the Common Shares of the Company held by ZKB Pharma Vision AG to Amgen; 
 
WHEREAS, the Company and the Rights Agent are parties to that certain Rights Agreement, dated as of December 11,
2002 (the “Rights Agreement”); 
 
WHEREAS, the Company desires to amend the Rights Agreement in connection with the execution and delivery of the Stock Purchase Agreement and to facilitate the transfer by ZKB Pharma Vision AG of all of the
Common Shares of the Company held by ZKB Pharma Vision AG to Amgen; and 
 
WHEREAS, the Board of Directors of the Company has approved this Amendment and authorized its appropriate officers to execute and deliver the same to the Rights Agent. 
 
NOW, THEREFORE, in
accordance with the procedures for amendment of the Rights Agreement set forth in Section 27 thereof, and in consideration of the foregoing and the mutual agreements herein set forth, the parties hereby agree as follows: 
 
1.    Capitalized terms that are
not otherwise defined herein shall have the meanings ascribed to them in the Rights Agreement. 
 
2.    The definition of “Excluded Stockholder” set forth in Section 1(h) of the Rights Agreement is restated in its entirety as follows: 
 
“Excluded Stockholder” shall
mean: (i) ZKB Pharma Vision AG (including its Affiliates and Associates); provided, however, that ZKB Pharma Vision AG (including its Affiliates and Associates) shall not be an Excluded Stockholder if ZKB Pharma Vision AG (including its
Affiliates and Associates) becomes the Beneficial Owner of more than 21% of the outstanding Common Shares without the prior approval of the 

Board of Directors; and (ii) Amgen Inc. (including its Affiliates and Associates) only with respect to any Common Shares that it beneficially
owns as a result of acquisitions (A) pursuant to that certain Stock Purchase Agreement by and between the Company and Amgen Inc. dated as of May 21, 2003 (as the same may be amended from time to time, the “Stock Purchase Agreement”) and/or
(B) of up to 11,358,238 shares of Common Shares (subject to appropriate adjustment for stock splits, stock dividends payable in shares of Common Shares or securities convertible into Common Shares, recapitalizations, capital reorganizations,
consolidations, mergers or similar transactions) from ZKB Pharma Vision AG (including its Affiliates and Associates) (the “ZKB Acquisition”) that ZKB Pharma Vision AG (including its Affiliates and Associates) beneficially owns as of May
21, 2003. 
 
3.    Section 1(o) of the Rights Agreement is hereby amended by adding as the final sentence thereto the following: 
 
Notwithstanding anything in this Agreement to the contrary, no Shares Acquisition Date shall be deemed to have occurred
solely as a result of (i) the approval, execution or delivery of the Stock Purchase Agreement or the ZKB Acquisition, (ii) the announcement of the Stock Purchase Agreement or the ZKB Acquisition or (iii) the acceptance for payment and purchase of
shares of Common Shares of the Company pursuant to the Stock Purchase Agreement or the ZKB Acquisition. 
 
4.    Section 3(a) of the Rights Agreement is hereby amended by adding as the final sentence thereto the
following: 
 
Notwithstanding
anything in this Agreement to the contrary, no Distribution Date shall be deemed to have occurred solely as a result of (i) the approval, execution or delivery of the Stock Purchase Agreement or the ZKB Acquisition, (ii) the announcement of the
Stock Purchase Agreement or the ZKB Acquisition or (iii) the acceptance for payment and purchase of shares of Common Shares of the Company pursuant to the Stock Purchase Agreement or the ZKB Acquisition. 
 
5.    Section 30 of the Rights
Agreement is hereby amended by adding as the final sentence thereto the following: 
 
Nothing in this Agreement shall be construed to give any holder of Rights or any other Person any legal or equitable
rights, remedies or claims under this Agreement by virtue of (i) the approval, execution or delivery of the Stock Purchase Agreement or the ZKB Acquisition, (ii) the announcement of the Stock Purchase Agreement or the ZKB Acquisition or (iii) the
acceptance for payment and purchase of shares of Common Shares of the Company pursuant to the Stock Purchase Agreement or the ZKB Acquisition. 
 
6.    The Rights Agreement, as amended by this Amendment, shall remain in full force and effect in accordance
with its terms. 
 

2 

 
7.    All the covenants and provisions of this Amendment by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit of their respective successors and assigns hereunder.

 
8.    If any term,
provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall
remain in full force and effect and shall in no way be affected, impaired or invalidated. 
 
9.    This Amendment shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by, and construed in accordance
with, the laws of such State applicable to contracts to be made and performed entirely within such State. 
 
10.    This Amendment may be executed in any number of counterparts and each of such counterparts shall for all
purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 
 
11.    The Company hereby certifies to the Rights Agent that this Amendment is in compliance with Section 27 of
the Rights Agreement. 
 

3 

 
IN WITNESS WHEREOF, the parties herein have caused this Amendment to be duly executed and attested, all as of the date and year first above written. 
 

	 TULARIK INC.

	
	 By:
	 	 /s/    DAVID V.
GOEDDEL        

	 	 	 Name: David V. Goeddel, Ph.D.
 Title: Chief Executive Officer

 

	
	 Attest:
	 	 /s/    WILLIAM J. RIEFLIN
        

	 	 	 Name: William J. Rieflin
 Title: Secretary

 

	 WELLS FARGO BANK MINNESOTA,
N.A.

	
	 By:
	 	 /s/    BEVERLY A.
ROBINSON        

	 	 	 Name: Beverly A. Robinson
 Title: Vice President

 

	
	 Attest:
	 	 /s/    JENNIFER L.
LENO        

	 	 	 Name: Jennifer L. Leno
 Title: Officer

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]